TwinStrand Biosciences, led by Jesse Salk, raises $50M Series B from Section 32 to scale ultra-accurate gene-sequencing

TwinStrand Biosciences, co-founded and led by Jesse Salk, raised $50 million in a Series B led by Section 32 to expand its high-accuracy gene-sequencing technology for detecting rare mutations with applications in cancer detection, therapy monitoring, and safety testing.